Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
8.38
+0.10 (1.21%)
Mar 31, 2025, 4:00 PM EDT - Market closed
Amneal Pharmaceuticals Revenue
In the year 2024, Amneal Pharmaceuticals had annual revenue of $2.79B with 16.73% growth. Amneal Pharmaceuticals had revenue of $730.52M in the quarter ending December 31, 2024, with 18.40% growth.
Revenue (ttm)
$2.79B
Revenue Growth
+16.73%
P/S Ratio
0.92
Revenue / Employee
$336,621
Employees
8,300
Market Cap
2.60B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.79B | 400.35M | 16.73% |
Dec 31, 2023 | 2.39B | 181.30M | 8.20% |
Dec 31, 2022 | 2.21B | 118.64M | 5.67% |
Dec 31, 2021 | 2.09B | 101.15M | 5.08% |
Dec 31, 2020 | 1.99B | 366.15M | 22.51% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
AMRX News
- 12 days ago - Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued - Seeking Alpha
- 21 days ago - Amneal to Participate at Upcoming Investor Conference - Business Wire
- 4 weeks ago - Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA - Business Wire
- 4 weeks ago - Amneal Pharmaceuticals, Inc. (AMRX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Amneal Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 5 weeks ago - Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock - Benzinga
- 5 weeks ago - Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide - Business Wire
- 2 months ago - Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025 - Business Wire